MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Neoplasms Clinical Trial

— MOCA-2  

Official title:

MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03299855
• Other study ID #: 2017-A01079-44
• Status: Completed
• Phase: N/A
• Start date: October 13, 2017
• Est. completion date: October 13, 2023

Study information

• Verified date: September 2023
• Source: Centre Francois Baclesse
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study concerns elderly patients with cancer with onco-geriatric assessment.

This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 104
• Est. completion date: October 13, 2023
• Est. primary completion date: October 13, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Patient aged over 70 years

• Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.

• Patient candidate for oncogeriatric assessment

• Patient agree to participate in the study

• Using the French language

Exclusion Criteria:

• Primary central nervous system or cerebral metastasis

• Evolutionary psychiatric pathology known (e.g. schizophrenia)

• Severe Visual and / or Auditory Impairment

• Patients unable to respond to cognitive tests

• Patient (s) deprived of liberty, under guardianship or curatorship

• Refusal of participation

Related Conditions & MeSH terms

• Cognition Disorders
• Cognitive Dysfunction
• Neoplasms

Intervention

Other:
• Passation of neuropsychological test
Passation of MoCA and MMS tests associated with neuropsychological test

Locations

Country	Name	City	State
France	Centre François Baclesse	Caen
France	CHU	Caen
France	CH	Cherbourg
France	Ch Compiegne	Compiègne
France	Centre Henri Becquerel	Rouen
France	Centre Hospitalier	Saint-Lô

Sponsors (2)

Lead Sponsor	Collaborator
Centre Francois Baclesse	UCOG (Unite de coordination en Onco-Gériatrie)

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the sensitivity of MoCA test	MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%	Up 2 months after inclusion, before initiation of treatment